A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Safety and Response Results from the Prospective Phase II Trial (NCT01849783)
Christopher Strouse(University of Iowa Hospitals and Clinics), Yogesh Jethava(University of Iowa), Michael H. Tomasson(University of Iowa), Sarah L. Mott(University of Iowa), Allyson Schultz(University of Iowa Hospitals and Clinics), Praveen Vikas(University of Iowa), Kalyan Nadiminti(University of Iowa Hospitals and Clinics), Umar Farooq(Wake Forest University), Jillna Claus(University of Iowa Hospitals and Clinics), Margarida Silverman(University of Iowa Hospitals and Clinics), Gabrielle Berns(University of Iowa Hospitals and Clinics)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
|New England Journal of Medicine|2023|437